Analyst firms · Oppenheimer · INCY
Oppenheimer INCY price target and rating history
Incyte Corp. (INCY) · Health Care
Oppenheimer rates Incyte Corp. (INCY) Outperform with a $144 price target, as of its latest action on Oct 30, 2026. It has published 3 rating actions on INCY since November 2021, including 1 upgrade and 1 downgrade. Across 9 firms with a INCY price target in the last 12 months, the median target is $119. Oppenheimer's $144 is 21% above that.
- Current rating
- Outperform
- Price target
- $144
- Median target, all firms
- $119
- Actions on INCY
- 3
Oppenheimer price target on INCY
Every Oppenheimer rating on INCY
- Oct 30, 2026
- Oct 8, 2025
- Nov 3, 2021
How other firms rate INCY
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Oppenheimer | Outperform | $144 | Oct 30, 2026 |
| Morgan Stanley | Equal-Weight | $119 | Oct 20, 2026 |
| Canaccord Genuity | Buy | $152 | Aug 20, 2026 |
| BMO Capital Markets | Market Perform | $94 | Jun 22, 2026 |
| Bernstein | Mkt Perform | $99 | May 22, 2026 |
| Jefferies | Hold | $94 | Mar 16, 2026 |
| H.C. Wainwright | Buy | $135 | Feb 5, 2026 |
| Wells Fargo | Equal Weight | $107 | Jan 20, 2026 |
| Mizuho | Outperform | $121 | Dec 8, 2025 |
Questions about Oppenheimer and INCY
- What is Oppenheimer's price target for INCY?
- Oppenheimer's latest stated price target for Incyte Corp. (INCY) is $144, from its action on Oct 30, 2026.
- What is Oppenheimer's rating on INCY?
- Oppenheimer rates INCY Outperform, a bullish rating, as of Oct 30, 2026.
- When did Oppenheimer last change its view on INCY?
- On Oct 30, 2026, Oppenheimer upgrades to Outperform from Perform, price target $144.
- How does Oppenheimer's INCY target compare with other analysts?
- Across 9 firms with a INCY price target in the last 12 months, the median target is $119. Oppenheimer's $144 is 21% above that.
More INCY rating histories
All Oppenheimer ratingsINCY news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.